{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-25-000110","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.150696+00:00","generated_at":"2026-05-17T00:19:19.682905+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Praxis reports Q3 net loss $73.9M; ulixacaltamide Phase 3 positive; pro forma cash ~$956M","bullets":["Ulixacaltamide met primary endpoints in both Essential3 Phase 3 studies for essential tremor; pre-NDA meeting with FDA scheduled Q4 2025.","Q3 net loss $73.9M vs $51.9M YoY; R&D expenses rose to $65.8M from $41.9M.","Cash and marketable securities $389.2M at Sept 30; October public offering added ~$567M net, extending runway into 2028.","Vormatrigine POWER1 study for focal onset seizures fully enrolled; topline expected 1H 2026.","Relutrigine interim analysis for SCN2A/SCN8A DEEs planned Q4 2025; if positive, NDA submission possible early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-25-000110","json":"https://secwatch.observer/filing/0001689548-25-000110.json","markdown":"https://secwatch.observer/filing/0001689548-25-000110.md","text":"https://secwatch.observer/filing/0001689548-25-000110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/0001689548-25-000110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/prax-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:19:19.682905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}